These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 30831643

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
    Schaff LR, Yan D, Thyparambil S, Tian Y, Cecchi F, Rosenblum M, Reiner AS, Panageas KS, Hembrough T, Lin AL.
    J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
    Limam S, Missaoui N, Abdessayed N, Mestiri S, Selmi B, Mokni M, Yacoubi MT.
    Ann Biol Clin (Paris); 2019 Jun 01; 77(3):307-317. PubMed ID: 31131831
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS, Kong DS, Seol HJ, Nam DH, Lee JI.
    J Neurooncol; 2017 Jul 01; 133(3):615-622. PubMed ID: 28536992
    [Abstract] [Full Text] [Related]

  • 7. The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma.
    Tini P, Pastina P, Nardone V, Sebaste L, Toscano M, Miracco C, Cerase A, Pirtoli L.
    Clin Neurol Neurosurg; 2016 Oct 01; 149():15-21. PubMed ID: 27450763
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C, Azevedo A, Esteves S, Marques AR, Martins C, Costa I, Mafra M, Bravo Marques JM, Roque L, Pojo M.
    BMC Cancer; 2019 Oct 17; 19(1):968. PubMed ID: 31623593
    [Abstract] [Full Text] [Related]

  • 11. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
    Yachi K, Watanabe T, Ohta T, Fukushima T, Yoshino A, Ogino A, Katayama Y, Nagase H.
    Int J Oncol; 2008 Sep 17; 33(3):469-75. PubMed ID: 18695875
    [Abstract] [Full Text] [Related]

  • 12. MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry.
    Trabelsi S, Mama N, Ladib M, Karmeni N, Haddaji Mastouri M, Chourabi M, Mokni M, Tlili K, Krifa H, Yacoubi MT, Saad A, H'mida Ben Brahim D.
    Clin Transl Oncol; 2016 Apr 17; 18(4):391-7. PubMed ID: 26289551
    [Abstract] [Full Text] [Related]

  • 13. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
    Shu C, Wang Q, Yan X, Wang J.
    Cancer Med; 2018 Aug 17; 7(8):3704-3712. PubMed ID: 29984907
    [Abstract] [Full Text] [Related]

  • 14. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma.
    Uno M, Oba-Shinjo SM, Camargo AA, Moura RP, Aguiar PH, Cabrera HN, Begnami M, Rosemberg S, Teixeira MJ, Marie SK.
    Clinics (Sao Paulo); 2011 Aug 17; 66(10):1747-55. PubMed ID: 22012047
    [Abstract] [Full Text] [Related]

  • 15. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A, Schmitz AL, Knoll A, Schneider M, Hlavac M, König R, Wirtz CR, Coburger J.
    Clin Neurol Neurosurg; 2018 Apr 17; 167():6-10. PubMed ID: 29425743
    [Abstract] [Full Text] [Related]

  • 16. Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
    von Rosenstiel C, Wiestler B, Haller B, Schmidt-Graf F, Gempt J, Bettstetter M, Rihani L, Wu W, Meyer B, Schlegel J, Liesche-Starnecker F.
    J Clin Pathol; 2020 Feb 17; 73(2):112-115. PubMed ID: 31422371
    [Abstract] [Full Text] [Related]

  • 17. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, Lee KS, Suh CO.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):661-7. PubMed ID: 22414280
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
    Kristensen LS, Michaelsen SR, Dyrbye H, Aslan D, Grunnet K, Christensen IJ, Poulsen HS, Grønbæk K, Broholm H.
    J Neuropathol Exp Neurol; 2016 Mar 01; 75(3):246-55. PubMed ID: 26883115
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.